CPC Scientific’s Rocklin facility is undergoing a major expansion to establish a 41,000 sq ft Center of Excellence for U.S.-based peptide API manufacturing. Construction is now underway—more updates coming soon.
At CPHI Frankfurt 2025, CPC Scientific will spotlight its position as a global leader in peptide and oligonucleotide CRDMO solutions. As the company’s largest event of the year, the showcase will emphasize innovation, regulatory excellence, and a proven track record of supporting partners worldwide. Visitors can connect with CPC Scientific’s leadership and scientific team at Booth 12.0F29 to explore new opportunities and collaborations.
The peptides found naturally in the human skin play essential roles in specific biological activities as signaling molecules of different physiological processes (i.e., homeostasis, defense, immunity). Due to their great biological activity, peptides are considered promising compounds with potential applications for certain cosmetic products. CPC Scientific possesses the manufacturing capabilities to assist with your cosmetic peptide projects, ranging from early discovery (mg quantities) to commercialization (100 kgs). Our pre-qualified workspace and adaptable approach enable us to expedite process development and commence production earlier than many other manufacturers.
Join us as we celebrate a proud milestone: the successful listing of Medtide Inc., parent company of CPC Scientific, on the main board of the Hong Kong Stock Exchange in June 2025. This moment marks a new chapter of growth, innovation, and global impact for our organization.
We are celebrating the successful listing of CPC Scientific’s parent company, MEDTIDE INC. on the Hong Kong Stock Exchange! MEDTIDE INC. announced today that its shares have officially commenced trading on the Main Board of The Stock Exchange of Hong Kong Limited under the stock code 03880. The successful listing marks a significant milestone in the Company’s global pharmaceutical development journey.
Sheri Ambriz, MBA took the stage at TIDES USA 2025 in San Diego, CA, to share insights on green approaches to peptide and peptide–oligonucleotide conjugate manufacturing.
